Ignite Creation Date:
2025-12-25 @ 12:07 AM
Ignite Modification Date:
2026-01-01 @ 5:39 PM
Study NCT ID:
NCT04869358
Status:
COMPLETED
Last Update Posted:
2025-05-16
First Post:
2021-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
Sponsor:
Novartis Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
COMB157GDE01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None